TSniffer : Unbiased de novo identification of RNA editing sites and quantification of editing activity in RNA-seq data
Preprint
Abstract
RNA editing by adenosine deaminases acting on RNA (ADARs) is an evolutionarily conserved posttranscriptional modification essential for organismal development and normal cell function. Three catalytically active ADARs are conserved in mammals: two isoforms of ADAR1 referred to as ADAR1-p150 and ADAR1-p110, as well as ADAR2. All recognize and edit double-stranded RNA (dsRNA) structures but demonstrate target specificity and selectivity that dictate the unique essential biological functions of the three enzymes. The editing activity of ADAR1-p150 suppresses autoimmune responses against self-RNA structures, whereas ADAR1-p110 and ADAR2 have other primary functions. To better understand the mechanism of target selection by ADARs, we developed TSniffer , which allows accurate de novo identification of edited transcripts and quantification of the extent of editing within each transcript. We found that 17-40% of protein coding transcripts in mice, ferrets, and humans are edited by ADARs. Individual transcripts can harbor hundreds and thousands of editing sites, mostly within inverted retrotransposable elements. For human transcripts, we found differential editing by ADAR1 and ADAR2, aligning with a supportive role for ADAR2, while some targets were dominantly edited by ADAR1. Relying only on RNA-seq data and reference genome, TSniffer represents a novel tool to decipher the role of ADAR editing in different physiological states including disease models. Its unbiased approach is suitable for any organism.Keywords
This publication has 85 references indexed in Scilit:
- Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunizationCell Reports, 2022
- ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activationCell Reports, 2021
- The role of RNA editing enzyme ADAR1 in human diseaseWIREs RNA, 2021
- Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancerCell, 2021
- Bi-allelic ADARB1 Variants Associated with Microcephaly, Intellectual Disability, and SeizuresThe American Journal of Human Genetics, 2020
- Human ADAR1 Prevents Endogenous RNA from Triggering Translational ShutdownCell, 2018
- Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated InflammationCell, 2018
- The RNA-Editing Enzyme ADAR1 Controls Innate Immune Responses to RNACell Reports, 2014
- One hundred million adenosine‐to‐inosine RNA editing sites: Hearing through the noiseBioEssays, 2014
- Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old players as modulators of the interferon responseCurrent Opinion in Immunology, 2011